Speakers from EFPIA, GS1, St James’s Hospital Dublin and 3C Integrity joined technology partners
Delegates from across Ireland came to Carton House, Dublin
To help prepare for the realities of the Falsified Medicines Directive (FMD), delegates from across Ireland came to Carton House, Dublin to attend Domino Printing Sciences’ Irish distributor Codico’s FMD Conference and learn from industry experts about the hidden challenges of implementing serialisation schemes.
A stellar line-up of speakers spoke to delegates about lessons learned from serialisation case studies, the best routes to compliance and the latest industry news concerning the FMD
A stellar line-up of speakers featuring Siobhain Duggan - business development director of healthcare at GSI Ireland; Christoph Krähenbühl - EFPIA board member; Feargal McGroarty - project manager at St James’s Hospital Dublin; and Ian Haynes, co-founder and CEO of 3C Integrity, spoke to delegates about lessons learned from serialisation case studies, the best routes to compliance and the latest industry news concerning the Directive.
Also joining conference, which was chaired by Craig Stobie, life sciences global sector manager at Domino, were a range of technology partners including Optel Vision, Marchesini, VisionID, SICK and Horizon, who demonstrated their compliance solutions.
Each speaker addressed different aspects of serialisation, with Siobhain Duggan outlining the importance of global standards as pharmaceutical manufacturers prepare for the FMD, Christoph Krähenbühl explaining EFPIA’s European Stakeholder Model for pan-European serialisation and product verification, and Feargal McGroarty talking delegates through the implementation of a ground-breaking serialisation and patient smartphone app scheme for treatment of those with haemophilia at St James's Hospital. To round-up, Ian Haynes discussed his practical experience of serialisation from his time as associate global engineering director at AstraZeneca – one of the first manufacturers to implement a serialisation trial.
Christoph Krahenbuhl from EFPIA addressed the delegates
Summing up the conference, Domino’s Stobie said: 'Many companies are dragging their heels and denying the impending arrival of EU FMD but even among the more proactive manufacturers there are marked differences.
'Poor companies see serialisation as an engineering challenge that can be fixed by simply buying new kit, and good companies are engaging with senior management, assembling cross-divisional teams and working with vendors to achieve compliance. Excellent companies, however, are those that will work to establish and realise the benefits FMD affords in terms of OEE, increased patient efficacy, improved inventory management and reduced wastage, among others.'